Human Laboratory Acquired ARBO-, ARENA-, and Hantavirus           Infections

Gaidamovich, S. Ya.; Butenko, A. M.; Leschinskaya, H. V.

doi:10.1177/109135050000500104

Cited by 12 publications

(14 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deaths from laboratory-acquired infections (LAIs) historically have been more frequently associated with viral agents, including HF viruses (CDC, 1970;Gaidamovish et al, 2000;Liefer et al, 1970;Miller, 2004;Mirza et al, 2005;Pike, 1976Pike, , 1979Sulkin et al, 1949). High virulence and lack of treatment or a protective vaccine may have contributed to deaths.…”

Section: Ribavirin Postexposure Prophylaxis For Laboratory Exposures mentioning

confidence: 97%

“…Infection is generally acquired in the natural setting by the bite of an infected tick or contact with infected animals. Individuals may also acquire disease by nosocomial transmission or in the laboratory setting (Gaidamovish et al, 2000;van Eeden et al, 1985). Fatality rates from CCHF have generally ranged from 15% to 30% (range 1% to 73%) Karti et al, 2004).…”

Section: Crimean Congo Hemorrhagic Fevermentioning

confidence: 97%

See 1 more Smart Citation

Experience with Ribavirin for Treatment and Postexposure Prophylaxis of Hemorrhagic Fever Viruses: Crimean Congo Hemorrhagic Fever, Lassa Fever, and Hantaviruses

Rusnak

2011

Appl Biosaf.

View full text Add to dashboard Cite

The increase in research laboratories with biosafety level-4 (BSL-4) capabilities may be associated with increased research with hemorrhagic fever (HF) viruses. The yellow fever vaccine and an investigational formalin-inactivated Rift Valley fever vaccine are the only vaccines for at-risk laboratory workers available in the United States against HF viruses. Ribavirin is a nucleoside analogue that has been demonstrated to have antiviral activity against a wide range of viruses, including many HF viruses. While intravenous (IV) ribavirin is not FDA-approved and oral ribavirin is approved only for treatment of hepatitis C in the United States, ribavirin has been used for treatment and postexposure prophylaxis for Crimean Congo hemorrhagic fever (CCHF), Lassa fever (LF), and hantaviruses, based mainly on in vitro sensitivity testing and efficacy studies in animals, but only on a limited number of studies and/or anecdotal experience in humans.The literature on both IV and oral ribavirin for treatment and postexposure prophylaxis for CCHF, LF, and hantaviruses is reviewed to aid occupational healthcare providers in the evaluation and recommendation of ribavirin to laboratory workers with exposures or illness from these HF viruses, which are associated with a significant morbidity and mortality.

show abstract

Section: Ribavirin Postexposure Prophylaxis For Laboratory Exposures mentioning

confidence: 97%

Section: Crimean Congo Hemorrhagic Fevermentioning

confidence: 97%

Experience with Ribavirin for Treatment and Postexposure Prophylaxis of Hemorrhagic Fever Viruses: Crimean Congo Hemorrhagic Fever, Lassa Fever, and Hantaviruses

Rusnak

2011

Appl Biosaf.

View full text Add to dashboard Cite

show abstract

“…In central Africa and regions of southern Europe, THOV has also been isolated from various ruminant species (61,74). The geographic distribution of DHOV includes primarily India and eastern Russia but also East Africa, Egypt, and other Mediterranean countries, where serologic data indicate circulation in ruminants as well as waterfowl (61,(75)(76)(77)(78). Migratory waterfowl are also reservoirs of influenza A viruses (78,79).…”

Section: Discussionmentioning

confidence: 99%

Upolu virus and Aransas Bay virus, Two Presumptive Bunyaviruses, Are Novel Members of the Family Orthomyxoviridae

Briese

Chowdhary

Rosa

et al. 2014

J Virol

View full text Add to dashboard Cite

Emerging and zoonotic pathogens pose continuing threats to human health and ongoing challenges to diagnostics. As nucleic acid tests are playing increasingly prominent roles in diagnostics, the genetic characterization of molecularly uncharacterized agents is expected to significantly enhance detection and surveillance capabilities. We report the identification of two previously unrecognized members of the family Orthomyxoviridae, which includes the influenza viruses and the tick-transmitted Thogoto and Dhori viruses. We provide morphological, serologic, and genetic evidence that Upolu virus (UPOV) from Australia and Aransas Bay virus (ABV) from North America, both previously considered potential bunyaviruses based on electron microscopy and physicochemical features, are orthomyxoviruses instead. Their genomes show up to 68% nucleotide sequence identity to Thogoto virus (segment 2; ϳ74% at the amino acid level) and a more distant relationship to Dhori virus, the two prototype viruses of the recognized species of the genus Thogotovirus. Despite sequence similarity, the coding potentials of UPOV and ABV differed from that of Thogoto virus, instead being like that of Dhori virus. Our findings suggest that the tick-transmitted viruses UPOV and ABV represent geographically distinct viruses in the genus Thogotovirus of the family Orthomyxoviridae that do not fit in the two currently recognized species of this genus. IMPORTANCE Upolu virus (UPOV) and Aransas Bay virus (ABV) are shown to be orthomyxoviruses instead of bunyaviruses, as previously thought.Genetic characterization and adequate classification of agents are paramount in this molecular age to devise appropriate surveillance and diagnostics. Although more closely related to Thogoto virus by sequence, UPOV and ABV differ in their coding potentials by lacking a proposed pathogenicity factor. In this respect, they are similar to Dhori virus, which, despite the lack of a pathogenicity factor, can cause disease. These findings enable further studies into the evolution and pathogenicity of orthomyxoviruses.

show abstract

“…The assistant developed a full-blown CCHF clinical picture including haemorrhages but survived after prolonged convalescence. A high initial CCHFV LD 50 titre on day 1 and seroconversion were demonstrated (Gaidamovich et al, 2000).…”

Section: Laboratory-acquired Infections While Handling Patient Samplesmentioning

confidence: 99%

“…In this instance, an underlying chronic hepatocholecystis may have contributed to the fatal outcome (Gaidamovich et al, 2000).…”

Section: Laboratory-acquired Infections During Researchmentioning

confidence: 99%

Biosafety standards for working with Crimean-Congo hemorrhagic fever virus

Weidmann

Avšič–Županc²,

Bino

et al. 2016

Journal of General Virology

View full text Add to dashboard Cite

Human Laboratory Acquired ARBO-, ARENA-, and Hantavirus Infections

Cited by 12 publications

References 4 publications

Experience with Ribavirin for Treatment and Postexposure Prophylaxis of Hemorrhagic Fever Viruses: Crimean Congo Hemorrhagic Fever, Lassa Fever, and Hantaviruses

Experience with Ribavirin for Treatment and Postexposure Prophylaxis of Hemorrhagic Fever Viruses: Crimean Congo Hemorrhagic Fever, Lassa Fever, and Hantaviruses

Upolu virus and Aransas Bay virus, Two Presumptive Bunyaviruses, Are Novel Members of the Family Orthomyxoviridae

Biosafety standards for working with Crimean-Congo hemorrhagic fever virus

Contact Info

Product

Resources

About